Demonstrate Efficacy and Safety of Metastatic Breast Cancer
NCT01084876 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475
Last updated 2025-02-11
Summary
The purpose of the study is to demonstrate equivalence
Conditions
Interventions
- DRUG
-
CT-P6
Administered every 3 weeks
- DRUG
-
Administered every 3 weeks
- DRUG
-
Administered every 3 weeks
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Investigational Site · Samsung Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2012-07-31
- Completion
- 2015-03-31
Countries
- South Korea
Study Locations
More Related Trials
-
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
NCT00281658 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
NCT02768415 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
NCT00031278 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')
NCT04946227 ·Status: UNKNOWN ·Phase: PHASE2
-
Metabolomics Explores Biomarkers for Metastatic Breast Cancer
NCT04302415 ·Status: UNKNOWN
-
Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
NCT00003540 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
NCT00051103 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01989676 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer
NCT00275041 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
NCT01276041 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
NCT02207361 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
NCT00532714 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
NCT05522491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
NCT03273595 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.
NCT06839547 ·Status: NOT_YET_RECRUITING
-
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
NCT02592746 ·Status: UNKNOWN ·Phase: PHASE2
-
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
NCT01526369 ·Status: COMPLETED ·Phase: PHASE3
-
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
NCT00031876 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer
NCT02142790 ·Status: UNKNOWN ·Phase: PHASE4
-
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
NCT00470704 ·Status: COMPLETED ·Phase: PHASE2
-
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
NCT03286842 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768701 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer
NCT00003539 ·Status: COMPLETED ·Phase: PHASE2